Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Halyard Health said late last month it tapped former Acelity prez & CEO Joseph Woody as its new chief executive officer, replacing a retiring Robert Abernathy.
Woody will also assume a seat on the board of directors, with former CEO Abernathy continuing on as board chair, the Alpharetta, Ga.-based company said. Read more
Medtronic‘s nano-sized Micra pacemaker was operating as expected after a 13-minute trip into space, the world’s largest medical device maker said last week.
The device was tested as part of Cubes in Space, a private education program that partners with the National Air & Space Administration to encourage students and educators to engage in science and space exploration. The Micra device used in the experiment was secured in a 4cm cube, according to Fridley, Minn.-based Medtronic. Read more
A team of researchers from the Netherlands evaluated three clinical trials involving 681 patients with chronic low back pain and found that radiofrequency denervation combined with exercise did not bring about a significant reduction of pain compared to exercise alone after 3 months.
Radiofrequency denervation is commonly used to treat chronic low back pain, but the team pointed out that evidence demonstrating its efficacy is lacking. Read more
Royal Philips last week said it paid an unspecified amount to acquire stealthy CardioProlific and the peripheral thrombectomy catheters it’s developing.
Philips said the deal for Hayward, Calif.-based CardioProlific is complementary to its $2.16 billion acquisition of Spectranetics and its own line of image-guided therapies. Read more
Nevro Corp. shares gained today in pre-market trading after the neuromodulation company reported preliminary sales numbers for its fiscal second quarter.
Redwood City, Calif.-based Nevro said it expects to post revenues of $77.5 million to $78.0 million for the three months ended June 30, which would be a 39.9% to 40.8% increase over the $55.4 million it posted during the same period last year. Read more